AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (265.9 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Perspective | Open Access

Protocol and statistical designs in classic clinical research—toripalimab series trial analysis

Yingjian He1,*, Li Bian2,*, Zefei Jiang2 ( )
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing 100142, China
Senior Department of Oncology, Chinese PLA General Hospital, Beijing 100071, China

*These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 23 Issue 3,
March 2026
Pages 338-342
DOI: 10.20892/j.issn.2095-3941.2025.0759

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
He Y, Bian L, Jiang Z. Protocol and statistical designs in classic clinical research—toripalimab series trial analysis. Cancer Biology & Medicine, 2026, 23(3): 338-342. https://doi.org/10.20892/j.issn.2095-3941.2025.0759

89

Views

6

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 27 November 2025
Accepted: 05 February 2026
Published: 01 March 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)